First urine-based cancer mutation monitoring test available from Trovagene

  First urine-based cancer mutation monitoring test available from Trovagene

Cell-free DNA assay transferred to CLIA laboratory for patient testing

PR Newswire

SAN DIEGO, Oct. 1, 2013

SAN DIEGO, Oct. 1, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ: TROV), a
developer of cell-free molecular diagnostics, today announced availability of
the first urine test for cancer mutation monitoring through the company's CLIA
laboratory. The robustness of Trovagene's ultra-sensitive assay procedure has
been demonstrated for detection of the BRAF V600E mutation from cell-free DNA
in urine. This mutation commonly occurs in melanoma, as well as several other
prevalent cancer types.


Of the more than 70,000 cases of melanoma diagnosed each year in the United
States, up to 70 percent harbor a BRAF-type mutation and of these, 80 percent
may be positive specifically for BRAF V600E.^1 There are several FDA-approved
targeted therapies for the treatment of BRAF-positive melanoma, making
mutational status monitoring an area of clinical interest among treating

Trovagene's cell-free BRAF^SM test is a laboratory-developed test (LDT)
designed to detect and monitor this mutation in metastatic cancer patients
with biopsy-proven V600E BRAF mutation in their tumor. It is the first
commercial assay within Trovagene's cancer monitoring portfolio performed
using a droplet digital PCR (ddPCR) platform. Using urine as a non-invasive,
systemic sample, the cell-free BRAF test could help physicians monitor changes
in mutation status for patients requiring therapy for cancers that have this
mutation. For patients with difficult-to-biopsy metastatic tumors, urine-based
mutation testing may also provide a viable alternative to check mutation
status as part of the initial treatment workup.

"We are developing a systemic, non-invasive cancer monitoring system," said
Mark Erlander, Ph.D., chief scientific officer for Trovagene. "Traditionally,
the mutation status of a tumor is determined using a tissue sample – a method
that has limited practicality for patient monitoring due to costs, tumor
heterogeneity and potential complications from the biopsy process. The ability
to detect the mutation signal in cell-free DNA isolated from urine overcomes
this limitation and meets a significant technical and clinical need."

The cell-free BRAF mutation assay has been tested across a range of solid
tumors including melanoma, non-small cell lung, rectal, and colon cancers,
indicating that urine-based mutation detection is applicable across many
cancer types. Additional clinical studies are ongoing to further understand
the full range of clinical applications for this and other Trovagene assays.

"This first assay represents a significant milestone for Trovagene," said
Antonius Schuh, Ph.D., chief executive officer of Trovagene. "Moving forward,
our goal is to apply our technology for improved monitoring of tumor dynamics,
leading to more effective management of cancer patients."

Trovagene has detected the BRAF V600E mutation in a variety of cancers, with
high levels of sensitivity and strong concordance with tissue biopsy. Further
expansion of the company's monitoring capabilities will include additional
mutational markers with known clinical utility, as well as known genomic
alterations that indicate resistance to therapy.

The Trovagene cell-free BRAF test is now available to healthcare providers for
patient testing. Physicians interested in utilizing this test should contact
Client Services at 888-391-7992. For more information, please visit

^1 - Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a
first step toward manageable disease. Clin Cancer Res 2011; 17(7):1658-63

About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its patented
technology for the detection of cell-free DNA and RNA, short nucleic acid
fragments, originating from normal and diseased cell death that can be
isolated and detected from urine. Trovagene has a strong intellectual property
asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and
European patent applications and issued patents that cover testing for HPV and
other infectious diseases, cancer, transplantation, prenatal and genetic

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend," among others.
These forward-looking statements are based on Trovagene's current expectations
and actual results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to,
substantial competition; our ability to continue as a going concern; our need
for additional financing; uncertainties of patent protection and litigation;
uncertainties of government or fourth party payer reimbursement; limited sales
and marketing efforts and dependence upon fourth parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance with FDA
regulations. As with any medical diagnostic tests under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. There are no guarantees that future
clinical trials discussed in this press release will be completed or
successful or that any product will receive regulatory approval for any
indication or prove to be commercially successful. Trovagene does not
undertake an obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in Trovagene's Form 10-K for
the year ended December 31, 2012 and other periodic reports filed with the
Securities and Exchange Commission.


Trovagene, Inc.

Stephen Zaniboni
Chief Financial Officer
Trovagene, Inc.

SOURCE Trovagene, Inc.

Press spacebar to pause and continue. Press esc to stop.